Fabry disease exhibiting recurrent stroke and persistent inflammation

Internal Medicine

Volumn 49, Issue 20, 2010, Pages 2247-2252

  Kikumoto, Yoko ^a   Kai, Yasufumi ^b   Morinaga, Hiroshi ^a   Iga Murahashi, Mutsunori ^b   Matsuyama, Mikitaro ^b   Sasaki, Takashi ^b   Maruyama, Hiroki ^c   Shimotori, Masaaki ^c   Makino, Hirofumi ^a   Sugiyama, Hitoshi ^a   Okayama, Akihiko ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Central nervous system; Chronic inflammation; Enzyme replacement therapy; Fabry disease; Ocular involvement; Recurrent strokes

Indexed keywords

ALPHA GALACTOSIDASE; C REACTIVE PROTEIN; FABRAENZYME; GAMMA INTERFERON; INTERLEUKIN 10; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT ALPHA GALACTOSIDASE; RECOMBINANT ENZYME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; BRAIN INFARCTION; CASE REPORT; CLINICAL FEATURE; DRUG MEGADOSE; EDEMA; ELECTROCARDIOGRAM; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; ERYTHROCYTE SEDIMENTATION RATE; FABRY DISEASE; FEVER; HEMANGIOKERATOMA; HEPATOMEGALY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INFLAMMATION; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RETINA ARTERY OCCLUSION; RETINOPATHY; STROKE; SYSTOLIC HEART MURMUR; VISUAL DISORDER;

ADULT; ALPHA-GALACTOSIDASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CEREBRAL INFARCTION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEVER; HUMANS; INFLAMMATION; MALE; MUTATION, MISSENSE; RECOMBINANT PROTEINS; RECURRENCE; RETINAL ARTERY OCCLUSION; RETINAL DISEASES; YOUNG ADULT;

EID: 78449306112     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3724     Document Type: Article

References (23)

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry Disease. In: The Metabolic and Molecular Bases of Inherited Disease, Vol.3, 8th ed. Scriver CR, Beaudet AL, Sly WS, et al, Eds. McGraw Hill, New York, 2001: 3733-3774.
2. Eng CM, Niehaus DJ, Enriquez Al, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet 3:1795-1799, 1994.
3. Yokoi T, Shinoda K, Ohno I, Kato K, Miyawaki T, Taniguchi N. A 3́ splice site consensus sequence mutation in the intron 3 of the alpha-galactosidase A gene in a patient with Fabry disease. Jinrui Idengaku Zasshi 36: 245-250, 1991 (in Japanese).
4. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53: 1186-1197,1993.
5. Sakuraba H, Oshima A, Fukuhara Y, et al. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 47: 784-789,1990.
6. Shimotori M, Maruyama H, Nakamura G, et al. Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum Mutat 29: 331-340, 2008.
7. Fellgiebel A, Muller MJ, Ginsberg L. CNS manifestation of Fabry's disease. Lancet Neurol 5: 791-795, 2006.
8. Kolodny EH, Pastores GM. Anderson-Fabry disease: Extrarenal, neurologic manifestations. J Am Soc Nephrol 13: S150-S153, 2002.
9. Rolfs A, Bottcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366: 1794-1796, 2005.
10. Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 41: 78-81,2010.
11. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40: 788-794, 2009.
12. Utsumi K, Ueda K, Watanabe M, et al. Thrombosis in Japanese patients with Fabry disease. J Neurol Sci 283: 83-85, 2009.
13. Moore DF, Altarescu G, Ling GSF, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33: 525-531, 2002.
14. Schiffmann R, Rapkiewicz A, Abu-Asab M, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 448: 337-343, 2006.
15. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease. Ann Intern Med 146: 77-86, 2007.
16. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374: 1986-1996, 2009.
17. Kleinert J, Dehout F, Schwarting A, et al. Anemia is a new complication in Fabry disease: Data from the Fabry outcome survey. Kidney Int 67: 1955-1960, 2005.
18. Safyan R, Whybra C, Beck M, Elstein D, Altarescu G. An association study of inflammatory cytokine gene polymorphisms in Fabry disease. Eur Cytokine Netw 17: 271-275, 2006.
19. Halligan C, Heese BA, Mellor G, Michels VV, Reed A. A boy with fever and whorl keratopathy. J Rheumatol 33: 1210-1211, 2006.
20. Altarescu G, Chicco G, Whybra C, et al. Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease. J Inherit Metab Dis 31: 117-123, 2008.
21. Vedder AC, Biro E, Aerts JM, Nieuwland R, Sturk G, Hollak CE. Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. Nephrol Dial Transplant 24: 3074-3081, 2009.
22. Saip S, Uluduz D, Erkol G. Fabry disease mimicking multiple sclerosis. Clin Neurol Neurosurg 109: 361-363, 2007.
23. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestation of 366 patients in the Fabry outcome survey. Eur J Clin Invest 34: 236-242, 2004.